Cargando…
Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy
BACKGROUND: The aim of the study was to investigate potential prognostic microRNA (miRNA) biomarkers for patients with early stage pancreatic ductal adenocarcinoma (PDAC) after pancreaticoduodenectomy using a miRNA-sequencing (miRNA-seq) data set from The Cancer Genome Atlas (TCGA). A miRNA expressi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089101/ https://www.ncbi.nlm.nih.gov/pubmed/30127641 http://dx.doi.org/10.2147/CMAR.S168351 |
_version_ | 1783346962968346624 |
---|---|
author | Liao, Xiwen Wang, Xiangkun Huang, Ketuan Yang, Chengkun Yu, Tingdong Han, Chuangye Zhu, Guangzhi Su, Hao Huang, Rui Peng, Tao |
author_facet | Liao, Xiwen Wang, Xiangkun Huang, Ketuan Yang, Chengkun Yu, Tingdong Han, Chuangye Zhu, Guangzhi Su, Hao Huang, Rui Peng, Tao |
author_sort | Liao, Xiwen |
collection | PubMed |
description | BACKGROUND: The aim of the study was to investigate potential prognostic microRNA (miRNA) biomarkers for patients with early stage pancreatic ductal adenocarcinoma (PDAC) after pancreaticoduodenectomy using a miRNA-sequencing (miRNA-seq) data set from The Cancer Genome Atlas (TCGA). A miRNA expression-based prognostic signature was generated, and the potential role of target genes in overall survival (OS) in patients with PDAC was examined. METHODS: A miRNA-seq data set of 112 PDAC patients who underwent pancreaticoduodenectomy was obtained from TCGA. Survival analysis was performed to identify potential prognostic biomarkers. RESULTS: Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function. The 11-miRNA prognostic signature showed good performance for prognosis prediction (adjusted P<0.0001, adjusted hazard ratio =4.285, 95% confidence interval =2.146–8.554), and the time-dependent receiver operating characteristic analysis showed an area under the curve of 0.864, 0.877, and 0.787 for 1-, 2-, and 3-year PDAC OS predictions, respectively. Comprehensive survival analysis suggested that the prognostic signature could serve as an independent prognostic factor for PDAC OS and performs better in prognosis prediction than other traditional clinical indicators. Functional assessment of the target genes of the miRNAs indicated that they were significantly enriched in multiple biological processes and pathways, including cell proliferation, cell cycle biological processes, the forkhead box O, mitogen-activated protein kinase, Janus kinase/signal transducers and activators of transcription signaling pathways, pathways in cancer, and the ErbB signaling pathway. Several target genes of these miRNAs were also associated with PDAC OS. CONCLUSION: The present study identified a novel miRNA expression signature that showed potential as a prognostic biomarker for PDAC after pancreaticoduodenectomy. |
format | Online Article Text |
id | pubmed-6089101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60891012018-08-20 Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy Liao, Xiwen Wang, Xiangkun Huang, Ketuan Yang, Chengkun Yu, Tingdong Han, Chuangye Zhu, Guangzhi Su, Hao Huang, Rui Peng, Tao Cancer Manag Res Original Research BACKGROUND: The aim of the study was to investigate potential prognostic microRNA (miRNA) biomarkers for patients with early stage pancreatic ductal adenocarcinoma (PDAC) after pancreaticoduodenectomy using a miRNA-sequencing (miRNA-seq) data set from The Cancer Genome Atlas (TCGA). A miRNA expression-based prognostic signature was generated, and the potential role of target genes in overall survival (OS) in patients with PDAC was examined. METHODS: A miRNA-seq data set of 112 PDAC patients who underwent pancreaticoduodenectomy was obtained from TCGA. Survival analysis was performed to identify potential prognostic biomarkers. RESULTS: Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function. The 11-miRNA prognostic signature showed good performance for prognosis prediction (adjusted P<0.0001, adjusted hazard ratio =4.285, 95% confidence interval =2.146–8.554), and the time-dependent receiver operating characteristic analysis showed an area under the curve of 0.864, 0.877, and 0.787 for 1-, 2-, and 3-year PDAC OS predictions, respectively. Comprehensive survival analysis suggested that the prognostic signature could serve as an independent prognostic factor for PDAC OS and performs better in prognosis prediction than other traditional clinical indicators. Functional assessment of the target genes of the miRNAs indicated that they were significantly enriched in multiple biological processes and pathways, including cell proliferation, cell cycle biological processes, the forkhead box O, mitogen-activated protein kinase, Janus kinase/signal transducers and activators of transcription signaling pathways, pathways in cancer, and the ErbB signaling pathway. Several target genes of these miRNAs were also associated with PDAC OS. CONCLUSION: The present study identified a novel miRNA expression signature that showed potential as a prognostic biomarker for PDAC after pancreaticoduodenectomy. Dove Medical Press 2018-08-10 /pmc/articles/PMC6089101/ /pubmed/30127641 http://dx.doi.org/10.2147/CMAR.S168351 Text en © 2018 Liao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Liao, Xiwen Wang, Xiangkun Huang, Ketuan Yang, Chengkun Yu, Tingdong Han, Chuangye Zhu, Guangzhi Su, Hao Huang, Rui Peng, Tao Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy |
title | Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy |
title_full | Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy |
title_fullStr | Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy |
title_full_unstemmed | Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy |
title_short | Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy |
title_sort | genome-scale analysis to identify prognostic microrna biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089101/ https://www.ncbi.nlm.nih.gov/pubmed/30127641 http://dx.doi.org/10.2147/CMAR.S168351 |
work_keys_str_mv | AT liaoxiwen genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT wangxiangkun genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT huangketuan genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT yangchengkun genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT yutingdong genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT hanchuangye genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT zhuguangzhi genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT suhao genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT huangrui genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy AT pengtao genomescaleanalysistoidentifyprognosticmicrornabiomarkersinpatientswithearlystagepancreaticductaladenocarcinomaafterpancreaticoduodenectomy |